Physician profile
John M Cox
NPI 1548216369
$903.05
in general payments reported to CMS, 2019-2025
14 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.91 · 2020: $43.75 · 2021: $20.61 · 2022: $61.50 · 2023: $125 · 2024: $181 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $331.06 | 2021-2025 | Myrisk |
| Acera Surgical, INC. | $126.57 | 2025 | Restrata Wound Matrix |
| Astellas Pharma US INC | $124.95 | 2023 | Veozah |
| Baxter Healthcare | $53.69 | 2020-2025 | Tisseel |
| Tela Bio, INC. | $45.39 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Solventum Corporation | $36.43 | 2025 | Prevena |
| Mayne Pharma Commercial LLC | $34.24 | 2025 | |
| Mimedx Group, INC. | $29.25 | 2024-2025 | |
| Ethicon US, LLC | $23.51 | 2020 | |
| Evofem Biosciences, INC. | $22.61 | 2022 | |
| Bioptics, INC. | $20.91 | 2019 | |
| Davol INC. | $19.38 | 2025 | Arista |
| Smith+Nephew, INC. | $17.91 | 2025 | Pico 14 |
| Elucent Medical | $17.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.